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Abstract Hyperhomocysteinemia is a well-known independent marker factor for
atherothrombotic diseases and may result from acquired and genetic influences.
Several polymorphisms are suspected to be associated with hyperhomocysteinemia,
but data are limited and inconsistent. High-throughput genotyping technologies,
such as GenomeLab SNPStream, are now available. Moreover, an appropriate
selection of SNPs to be analyzed could represent a strong resource to define the role
of genetic risk factors. We developed a multiplex PCR-oligonucleotide extension
approach by GenomeLab platform. We selected 72 SNPs based on their putative
function and frequency in the candidate genes AHCY, BHMT, BHMT2, CBS,
ENOSF1, FOLH1, MTHFD1, MTHFR, MTR, MTRR, NNMT, PON1, PON2,
SLC19A1, SHMT1, TCN2, and TYMS. We were able to analyze 57 of the SNPs
(79%). For MTHFR C677T and A1298C and MTR A2756G SNPs, we compared
data obtained with an electronic microchip technology and found 99.2% concor-
dance. We also performed a haplotype analysis. This approach could represent a
useful tool to investigate the genotype–phenotype correlation and the association of
these genes with hyperhomocysteinemia and correlated diseases.
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Introduction
Hyperhomocysteinemia (hyperHcy) has been implicated as an independent marker
factor for cardiovascular diseases (McCully 1969; Eikelboom et al. 1999) and is
associated with various other diseases and/or clinical conditions including
Alzheimer’s disease (Clarke et al. 1998), neural tube defects (Blom et al. 2006),
schizophrenia (Applebaum et al. 2004), end-stage renal disease (Van Guldener and
Stehouwer 2003), osteoporosis (Villadsen et al. 2005) and non-insulin-dependent
diabetes (De Luis et al. 2005; Rudy et al. 2005). Moreover, perturbations in
methionine metabolism and methylation reactions may be involved in cancer
processes, such as colorectal cancer (Singh et al. 2003; Kim 2005; Sharp and Little
2004). Homocysteine (Hcy) is a highly reactive, sulfur-containing amino acid
formed during methionine metabolism in the cell. It is a key branch-point
intermediate in the ubiquitous methionine cycle, the function of which is to generate
one-carbon methyl groups for transmethylation reactions that are essential for several
biological processes. It is estimated that 5 to 7% of the general population have mild
to moderate hyperHcy. Mild hyperHcy may result from both acquired (e.g., vitamin
deficiencies) and genetic influences (Fowler 2005; Gellekink et al. 2005). Although
hyperHcy has been associated with several diseases, the mechanism of Hcy-induced
deleterious effects is not fully elucidated. Among the various mechanisms proposed
to explain the harmful effects of Hcy, one is that it modulates the expression of
certain genes that may lead to several pathological conditions (Castro et al. 2005).
Hcy-induced regulation of the expression of genes through the interference of
DNA epigenetic phenotype modification (alteration of DNA methylation) (Castro
et al. 2006) or by hitherto unknown mechanisms is predicted to lead to pathological
conditions either directly or indirectly. Data from the literature provide evidence of
135 genes that either modulate the levels of Hcy (23 genes) or are modulated (112
genes) by elevated levels of Hcy (Sharma et al. 2006).
Several genetic polymorphisms in genes coding for enzymes involved in Hcy
metabolism are demonstrated or suspected to be associated with hyperHcy. Some of
these polymorphisms have a large number of data in the literature, even if not
always consistent [e.g., C677T and A1298C in 5,10-methylenetetrahydrofolate
reductase (MTHFR), A2756G in methionine synthase (MTR), G80A in solute
carrier family 19 (folate transporter), member 1 (SLC19A1), C776G (TCN2)]. In
some cases (e.g., C677T and A1298C MTHFR polymorphisms), the rare allele is
associated with reduced enzyme activity in vitro (Frosst et al. 1995; Weisberg et al.
1998). At present, for a large number of genes involved in methionine metabolism,
comprising those most studied, a deeper evaluation of SNPs might be necessary to
determine whether they represent a genetic risk for Hcy metabolism perturbation
and correlated diseases.
Besides the putative role in influencing homocysteine and homocysteine-
thiolactone levels (Perla-Kajan et al. 2007), polymorphisms in enzymes involved in
methionine metabolism may also play a role in altering DNA methylation reactions
and thus genetic stability and gene expression (Waterland 2006). Therefore, the
pivotal role of methionine metabolism in determining levels of highly reactive
homocysteine and in altering genetic stability and gene expression leads us to
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assume that a study of several polymorphisms in different genes involved in this
pathway might be significant.
In the present study, the SNP selection was to permit construction of informative
haplotypes in different selected candidate genes, independent of their known role in
influencing Hcy levels, to use them in future susceptibility and association studies.
Thus, we evaluated a high-throughput analytical strategy using the GenomeLab
SNPStream technology (Beckman Coulter, Fullerton, CA), based on multiplex
primer extension reactions. It can be applied in the evaluation of genotype-phenotype
correlation and association studies aimed at investigating the role of several genetic
polymorphisms in different genes involved in methionine metabolism.
Materials and Methods
Selection of Polymorphisms
We selected SNPs in candidate genes according to their demonstrated or putative
function on the basis of literature data, localization in the promoter or regulatory
region or exons (SNP causing amino acid substitution), and/or with heterozygosity
values greater than 0.300, extracted from the dbSNP database (NCBI, National
Center for Biotechnology Information, Bethesda, http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=snp&cmd=search&term=). The annotation of each SNP and
its frequency in Caucasian populations were assessed in dbSNP NCBI and
ENSEMBL (http://www.ensembl.org/index.html) databases.
Blood Collection and DNA Extraction
Peripheral blood samples were collected from 376 consecutive, Italian, apparently
healthy subjects (24–98 years old, median age: 72; male/female: 207/169). To
enroll healthy subjects, we excluded those with a history of cardiovascular disease
or venous thromboembolic events, evaluated by a questionnaire structured to
identify symptom-free subjects and to exclude those who were suspected of having
any form of vascular disease. No subject had abnormal liver or renal function.
Genomic DNA was isolated from peripheral whole blood cells using the
Flexigene DNA kit (Qiagen, Germany).
Genotyping of 72 Polymorphisms by GenomeLab SNPStream DNA Microarray
Technology
All the SNPs were analyzed with GenomeLab SNPStream DNA microarray
technology.
Primer Design
Genomic DNA sequences encompassing the polymorphic sites were subjected to a
Blast search (Basic Local Alignment Sequence Tool; http://www.ncbi.nlm.nih.gov/
BLAST/) in order to demonstrate highly homologous and repetitive elements.
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Therefore, a specific software (http://www.autoprimer.com, Beckman Coulter,
Fullerton, CA) was used for the design of the 12 pairs of primers for the multiplex
PCR and of the 12 tagged extension primers for each panel. PCR primers were
designed to amplify a short sequence (90–175 bp) surrounding the polymorphic site
for each SNP of interest, while the single-strand tagged extension primers, com-
plementary to the 30 sequence flanking the SNP site, permitted the discrimination of
the various alleles (Supplementary Table A; data available from the corresponding
author on request).
Automation System
The liquid handling in all the reaction protocols is supported by Biomek FX
Workstation (Beckman Coulter, Fullerton, CA).
Multiplex PCR and Clean-up Reactions
Multiplex PCR was performed in an MJ thermocycler (MJ Research, Waltham,
MA) according to the recommended PCR condition: one denaturation cycle at 94C
for 1 min, 40 cycles with denaturation at 94C for 1 min, annealing at 55C for
30 s, and extension at 72C for 1 min, followed by a final extension at 72C for
1 min. The reaction was performed in a final volume of 5 ll with 4 ng genomic
DNA, 75 lM dNTP mix, 50 nM primer pool, 5 mM MgCl2, and 0.5 U Taq
polymerase (GoTaq, Promega, Milan, Italy) in PCR 1 9 buffer. PCR products were
purified by Exo-Sap reaction (0.67 U exonuclease I and 0.33 U shrimp alkaline
phosphatase in 3 ll mix volume), performed in an MJ thermocycler to degrade
unincorporated PCR primers and dNTPs (USB Corp., Cleveland), following the
recommended conditions: first step at 37C for 30 min and final incubation at 96C
for 10 min.
Primer Extension Reaction
Extension protocol was performed using an appropriate mix containing TAMRA
and Bodipy-fluorescein labeled dideoxynucleotides (ddNTPs) and a pool of 12
allele-specific tagged extension primers. The tagged extension primers can be
directed toward a specific location in each well (containing a 4 9 4 oligonucleotide
array) of the 384 SNPware plate, because of the presence of a tag at the 50-terminus
of the extension primer, complementary to the arrayed oligonucleotides. The
30-terminus of the tagged extension primers is complementary to the sequence
strictly adjacent to the SNP site (Denomme and Van Oene 2005) (Fig. 1). The
extension reaction permits the incorporation of dye-labeled dideoxynucleotides at
the 30-terminus of the tagged extension primer. In each 4 9 4 array, three positive
controls and one negative control were included to ensure accuracy in the genotype
determination (Fig. 1). The extension reaction was performed in an MJ thermocy-
cler according to the recommended extension conditions: a cycle at 96C for 3 min,
44 cycles with a first step at 94C for 20 sec and a second step at 40C for 11 sec,
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and final hold at 4C. The reaction was performed in a final volume of 15 ll with
0.04 ll SNP extension mix, 5.6 ll SNPware Extension Dilution Buffer, 0.3 ll SNP
20 9 extension mix, and 0.03 ll SNPware DNA polymerase (Beckman Coulter,
Fullerton, CA). The SNP 20 9 extension mix contains the dye-labeled dideoxy-
nucleotides, used in the primer extension reaction, and self-annealing
oligonucleotides that are extended with dye-labeled terminators; these probes serve
as positive controls in each well.
Hybridization Reaction
The primer extension products were transferred to the 384 SNPware plate,
previously washed three times with 1 9 SNPware Wash Buffer I, so that each
extended primer would hybridize in a specific way to one of the unique probes
arrayed in each well. A 12 ll volume of hybridization mix (Beckman Coulter,
Fullerton, CA) was added to each well of the plate containing the primer extension
products; thus, 8 ll of the previous mixture was transferred to the corresponding
well of the SNPware plate. The SNPware plate with the hybridization mix was
incubated at 42C for 2 h (±15 min) in a humid chamber. Thereafter, the SNPware
plate was washed three times, adding 1 9 SNPware Wash Buffer II to each well to
remove the probes not arrayed.
Fig. 1 (a) Extension primers complementary to the sequence adjacent to the SNP site, characterized by
the presence of a tag at the 50 end. The tagged extension primers can be recognized by oligonucleotides
located in specific positions in the 4 9 4 array. (b) The 4 9 4 array has 4 control locations and 12 probe
locations for 12 SNPs. Scanning images are shown on the right (blue/green laser detection)
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Data Analysis
The SNPware plate was analyzed with the GenomeLab SNPStream array imager.
Blue and green lasers (488 and 532 nm, respectively) detected the fluorescent color
of the extended base for each spot. GetGenos software performed the image analysis,
assigning the genotype to each SNP spot on the basis of the relative fluorescence
intensity for any SNP. Self-annealing oligonucleotides, extended with dye-labeled
ddNTPs as described previously (extension reaction) and hybridized to specific
probes in each 4 9 4 array, are used to get a correct grid alignment. The top-left
location of the 4 9 4 array contained a mixture of two probes hybridizing to self-
extending oligonucleotides that can incorporate both blue and green dye-labeled
ddNTPs (heterozygous control), while the top-right and the bottom-left positions had
probes that hybridized to self-extending oligonucleotides incorporating just blue or
green dye-labeled ddNTPs, respectively (homozygous controls) (Fig. 1). Moreover,
the bottom-right location had probes that were not self-extending and lacked
complementarity to any DNA in the reaction (negative control).
In the genotype analysis, three possible calls to each spot in the 384 SNPware plate
can be obtained and collected into three clusters, one representing the homozygous
XX genotype (as shown in the rightmost side of the graph), one representing the
heterozygous XY genotype (central cluster), and one representing the homozygous
YY genotype (as shown in the leftmost side of the graph) (Fig. 2) (Huang et al. 2004).
Plot data can be finally converted into an Excel format by the software itself,
registering the genotype observed for each SNP in the samples analyzed.
Genotyping Three Polymorphisms by Nanogen Technology
The MTHFR C677T (rs1801133), MTHFR A1298C (rs1801131), and MTR A2756G
(rs1805087) gene polymorphisms were evaluated by the NanoChip Molecular
Biology Workstation (NanoChip cartridge, Nanogen, San Diego, CA), using the
protocol extensively described in a previous paper (Giusti et al. 2004). MTHFR and
MTR gene sequences were obtained from GeneBank (http://www.ncbi.nlm.nih.gov,
accession nos. AL953897.6 and AC013268.5). The oligonucleotides used for
PCR and for hybridization, along with the melting, annealing, and stringency
temperatures, are reported in Supplementary Table B (data available from the
corresponding author on request). The software of the system directly assigned the
genotype to each sample.
Linkage Disequilibrium and Haplotype Analysis
To prepare data files for linkage disequilibrium by SNPalyze software and for
haplotype reconstruction analysis by Phase version 2.1 software, data files obtained
by GetGenos SNPStream software were processed in the R environment (http://
www.r-project.org).
Pairwise linkage disequilibrium was evaluated using SNPalyze software
(Dynacom, Chiba, Japan).
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The Phase version 2.1 software (Scheet and Stephens 2006) is an implementation
of the Bayesian method of haplotype reconstruction, allowing use of a priori
expectations to assign haplotypes correctly to individuals in a dataset. Phase uses a
Gibb’s sampling algorithm, a type of Markov chain-Monte Carlo algorithm, to
obtain an approximate sample from the posterior distribution of Pr(H|G), where H is
the unknown haplotype pair and G is the known genotype.
Results
We selected 72 SNPs in 17 candidate genes: 7 in MTHFD1 [methylenetetrahy-
drofolate dehydrogenase (NADP + dependent) 1, methenyltetrahydrofolate
cyclohydrolase, formyltetrahydrofolate synthetase], 5 in NNMT (nicotinamide
N-methyltransferase), 3 in PON1 (paraoxonase 1), 2 in PON2 (paraoxonase 2), 5 in
Fig. 2 Computer-displayed scatter plot of the TAMRA-Bodipy fluorescence associated with PON1
575G [ A SNP (rs662). The three clusters of genotypes are represented by green (YY), orange (XY), and
blue (XX)
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TCN2 (transcobalamin II), 4 in AHCY (S-adenosylhomocysteine hydrolase), 7 in
MTRR (5-methyltetrahydrofolate-homocysteine methyltransferase reductase), 5 in
BHMT (betaine-homocysteine methyltransferase), 3 in FOLH1 [folate hydrolase
(prostate-specific membrane antigen) 1], 5 in MTHFR [5,10-methylenetetrahydrof-
olate reductase (NADPH)], 6 in MTR (5-methyltetrahydrofolate-homocysteine
methyltransferase), 2 in TYMS (thymidylate synthetase), 1 in ENOSF1 (enolase
superfamily member 1), 3 in SHMT1 [serine hydroxymethyltransferase 1 (soluble)],
5 in SLC19A1 [solute carrier family 19 (folate transporter), member 1], 7 in CBS
(cystathionine-beta-synthase), and 2 in BHMT2 (betaine-homocysteine methyl-
transferase 2).
They were analyzed in six panels of 12 SNPs each, according to their nucleotide
substitution (1 AT, 1 CA, 1 GC, 1 GA, and 2 CT panels).
The conversion rate among the six panels ranged from 67 to 100%, with 12/12
SNPs working in 1 panel, 10/12 in 1 panel, 9/12 in 3 panels, and 8/12 in 1 panel.
Therefore, we could analyze 57 out of 72 (79.2%) SNPs. If we excluded the panel
with the higher number of failed SNPs, we observed a conversion rate of 81.7% for
oligonucleotides designed by Autoprimer software.
We genotyped 376 subjects. The genotype distribution and allele frequency of
the 57 SNPs are reported in Table 1. At the first analysis, the median number of
called samples was 340 (range: 136–368), with a median percentage of called
samples of 90.4 (range: 36.2–97.9%).
All the passed SNPs under study resulted in Hardy-Weinberg equilibrium.
For the polymorphisms C677T and A1298C in the MTHFR gene and A2756G
in the MTR gene, we compared data obtained with the high-throughput
GenomeLab SNPStream technology with those obtained with the low-to-medium
throughput Nanogen electronic microchip technology in 288 subjects. We found
a 99.2% concordance between the results obtained with the two technologies.
This concordance was observed for all of the samples independent of the
genotype and the SNPs studied. For the seven discordant samples, 6/7 discordant
genotypes had low fluorescence signals in the Nanogen analysis, and the
repetition of the PCR and Nanogen analysis confirmed the genotype identified by
the SNPStream technology. The direct sequencing of the 1/7 discordant genotype
with apparently the correct genotype with the two platforms demonstrated that
the correct genotype was that identified by SNPStream technology (data not
shown).
Pairwise Linkage Disequilibrium Measurement and Haplotype Reconstruction
The pairwise linkage disequilibrium between all pairs of SNP markers of a gene in
the subjects studied is reported in Supplementary Table C (data available from the
corresponding author on request), as indicated by the D0, r2, Akaike’s information
criterion, and P value for the chi-squared test (Stephens et al. 2001). Several genes
among those investigated showed a high percentage of SNP, with D0 values greater
than 0.5. These data suggested that sequence variants within the considered gene are
in strong disequilibrium.
Biochem Genet
123
T
a
b
le
1
G
en
o
ty
p
e
d
is
tr
ib
u
ti
o
n
an
d
al
le
le
fr
eq
u
en
cy
o
f
al
l
se
le
ct
ed
an
d
an
al
y
ze
d
S
N
P
s
G
en
e
A
cc
es
si
o
n
N
o
.
E
n
se
m
b
le
g
en
e
S
N
P
ID
R
eg
io
n
P
o
si
ti
o
n
a
P
an
el
P
as
se
d
\
F
ai
le
d
b
N
u
m
b
er
o
f
ca
ll
ed
g
en
o
ty
p
e
G
en
o
ty
p
e
d
is
tr
ib
u
ti
o
n
n
(%
)
A
ll
el
e
fr
eq
u
en
cy
V
al
id
at
io
n
st
at
u
s
A
H
C
Y
A
L
3
5
6
2
9
9
E
N
S
G
0
0
0
0
0
1
0
1
4
4
4
rs
8
1
9
1
4
6
5
0 u
tr
1
2
C
A
P
as
se
d
3
1
6
(8
4
.1
)
A
A
(
6
6
.7
)
A
C
(2
7
.0
)
C
C
(6
.3
)
C
=
0
.2
0
0
y
es
2
0
ce
n
-
q
1
3
.1
rs
7
2
7
1
5
0
1
in
tr
o
n
1
1
4
8
1
3
C
G
P
as
se
d
3
6
8
(9
7
.9
)
C
C
(9
9
.7
)
C
G
(0
.3
)
G
G
(0
.0
)
G
=
0
.0
0
1
y
es
rs
8
1
9
1
5
9
in
tr
o
n
1
2
7
2
0
1
A
T
F
A
IL
E
D
y
es
rs
4
2
3
9
in
tr
o
n
2
3
0
4
0
1
A
T
F
A
IL
E
D
y
es
B
H
M
T
A
C
0
0
8
5
0
2
.8
E
N
S
G
0
0
0
0
0
1
4
5
6
9
2
rs
6
5
1
8
5
2
in
tr
o
n
1
4
C
T
P
as
se
d
3
5
7
(9
4
.9
)
C
C
(2
9
.8
)
C
T
(5
1
.5
)
T
T
(1
8
.7
)
T
=
0
.4
5
0
y
es
5
q
1
3
.1
-q
1
5
rs
5
6
7
7
5
4
in
tr
o
n
7
3
5
6
5
C
T
P
as
se
d
3
3
7
(8
9
.6
)
C
C
(4
3
.4
)
C
T
(4
4
.5
)
T
T
(1
2
.1
)
T
=
0
.3
4
3
y
es
rs
3
7
3
3
8
9
0
ex
o
n
1
2
8
9
9
4
C
T
c
P
as
se
d
3
3
2
(8
8
.3
)
C
C
(4
6
.5
)
C
C
(3
9
.0
)
T
T
(1
4
.5
)
T
=
0
.3
4
0
y
es
rs
1
0
0
3
7
0
4
5
in
tr
o
n
1
3
5
1
0
1
A
T
F
A
IL
E
D
y
es
rs
5
8
5
8
0
0
3
0 u
tr
1
8
1
4
8
1
A
T
P
as
se
d
3
5
6
(9
4
.7
)
A
A
(5
9
.0
)
A
T
(3
6
.0
)
T
T
(5
.0
)
T
=
0
.1
8
0
y
es
B
H
M
T
2
A
C
0
0
8
5
0
2
.8
E
N
S
G
0
0
0
0
0
1
3
2
8
4
0
rs
6
4
4
1
9
1
in
tr
o
n
1
6
G
A
P
as
se
d
3
3
6
(8
9
.4
)
A
A
(6
8
.0
)
A
G
(2
8
.0
)
G
G
(4
.0
)
G
=
0
.1
7
7
y
es
5
q
1
3
rs
6
8
2
9
8
5
ex
o
n
8
3
4
4
4
C
T
P
as
se
d
3
5
2
(9
3
.6
)
T
T
(3
8
.9
)
T
C
(5
7
.1
)
C
C
(2
0
.0
)
C
=
0
.4
2
0
y
es
C
B
S
A
P
0
0
1
6
3
0
.1
E
N
S
G
0
0
0
0
0
1
4
8
4
5
0
P
ro
8
8
S
er
ex
o
n
1
5
4
2
4
C
T
P
as
se
d
3
6
4
(9
6
.8
)
C
C
(9
1
.0
)
C
T
(9
.0
)
T
T
(0
.0
)
T
=
0
.0
4
0
n
o
2
1
q
2
2
.3
A
la
1
1
4
V
al
ex
o
n
3
7
5
3
4
C
T
F
A
IL
E
D
n
o
G
ly
1
1
6
A
rg
ex
o
n
3
7
5
8
6
G
A
P
as
se
d
3
5
2
(9
3
.6
)
G
G
(1
0
0
)
G
A
(0
.0
)
A
A
(0
.0
)
A
=
0
.0
0
0
n
o
rs
2
3
4
7
0
6
ex
o
n
4
8
6
6
4
C
T
F
A
IL
E
D
y
es
rs
1
2
3
2
9
7
9
0
ex
o
n
7
0
3
2
5
C
T
F
A
IL
E
D
y
es
rs
1
8
0
1
1
8
1
ex
o
n
9
6
0
0
5
C
T
F
A
IL
E
D
n
o
rs
1
0
5
1
3
1
9
3
0 u
tr
1
6
3
4
9
3
C
G
c
P
as
se
d
3
5
6
(9
4
.7
)
G
G
(7
7
.0
)
G
C
(2
2
.0
)
C
C
(1
.0
)
C
=
0
.1
1
7
y
es
E
N
O
S
F
1
A
P
0
0
1
1
7
8
.4
E
N
S
G
0
0
0
0
0
1
3
2
1
9
9
rs
8
4
2
3
3
0 u
tr
1
4
7
7
6
d
2
C
A
P
as
se
d
1
2
8
(3
4
.0
)
A
A
(2
8
.0
)
A
C
(5
2
.0
)
C
C
(2
0
.0
)
A
=
0
.5
4
0
y
es
1
8
p
1
1
.3
2
F
O
L
H
1
A
C
1
1
0
7
4
2
.4
E
N
S
G
0
0
0
0
0
0
8
6
2
0
5
rs
2
0
2
6
7
6
ex
o
n
1
6
G
A
c
P
as
se
d
3
4
4
(9
1
.5
)
A
A
(6
7
.0
)
A
G
(3
1
.0
)
G
G
(2
.0
)
G
=
0
.1
7
0
y
es
1
1
p
1
1
.2
rs
2
0
2
6
8
0
ex
o
n
5
7
3
5
1
A
T
P
as
se
d
3
5
2
(9
3
.6
)
A
A
(5
.7
)
A
T
(3
3
.8
)
T
T
(6
0
.5
)
T
=
0
.2
2
0
y
es
H
4
7
5
Y
ex
o
n
3
5
6
1
6
5
C
T
F
A
IL
E
D
Biochem Genet
123
T
a
b
le
1
co
n
ti
n
u
ed
G
en
e
A
cc
es
si
o
n
N
o
.
E
n
se
m
b
le
g
en
e
S
N
P
ID
R
eg
io
n
P
o
si
ti
o
n
a
P
an
el
P
as
se
d
\
F
ai
le
d
b
N
u
m
b
er
o
f
ca
ll
ed
g
en
o
ty
p
e
G
en
o
ty
p
e
d
is
tr
ib
u
ti
o
n
n
(%
)
A
ll
el
e
fr
eq
u
en
cy
V
al
id
at
io
n
st
at
u
s
M
T
H
F
D
1
A
L
1
2
2
0
3
5
.6
E
N
S
G
0
0
0
0
0
1
0
0
7
1
4
rs
2
3
5
7
4
8
1
5
0 u
tr
1
1
A
T
P
as
se
d
3
3
6
(8
9
.4
)
A
A
(9
9
.0
)
A
T
(1
.0
)
T
T
(0
.0
)
T
=
0
.0
0
3
n
o
1
4
q
2
4
rs
1
0
7
6
9
9
1
5
0 u
tr
7
0
4
0
5
C
T
c
P
as
se
d
3
6
0
(9
5
.7
)
T
T
(3
0
.1
)
T
C
(4
8
.4
)
C
C
(2
1
.5
)
C
=
0
.4
5
7
y
es
rs
3
7
8
3
7
3
2
In
tr
o
n
7
7
9
3
1
A
T
P
as
se
d
1
3
6
(3
6
.2
)
A
A
(1
0
0
)
A
T
(0
.0
)
T
T
(0
.0
)
T
=
0
.0
0
0
y
es
rs
8
0
0
3
3
7
9
In
tr
o
n
2
5
5
9
8
2
C
A
P
as
se
d
2
6
4
(7
0
.2
)
A
A
(4
4
.5
)
A
C
(4
4
.5
)
C
C
(1
.0
)
C
=
0
.3
3
4
y
es
rs
1
9
5
0
9
0
2
E
x
o
n
3
2
6
3
8
5
C
T
P
as
se
d
3
0
6
(8
1
.4
)
C
C
(7
8
.4
)
C
T
(2
0
.3
)
T
T
(1
.3
)
T
=
0
.1
1
4
y
es
rs
4
9
0
2
2
8
3
E
x
o
n
3
4
8
7
0
4
C
T
P
as
se
d
3
3
2
(8
8
.3
)
C
C
(9
8
.0
)
C
T
(2
.0
)
T
T
(0
.0
)
T
=
0
.0
0
9
y
es
rs
2
2
3
6
2
2
5
E
x
o
n
5
9
1
9
9
6
G
A
P
as
se
d
3
4
8
(9
2
.5
)
G
G
(3
7
.0
)
G
A
(4
4
.0
)
A
A
(1
9
.0
)
A
=
0
.4
1
5
y
es
M
T
H
F
R
A
L
9
5
3
8
9
7
.6
E
N
S
G
0
0
0
0
0
1
7
7
0
0
0
rs
1
8
0
1
1
3
3
E
x
o
n
1
2
C
A
P
as
se
d
3
1
6
(8
4
.0
)
C
C
(1
1
.0
)
C
A
(4
0
.0
)
A
A
(4
9
.0
)
A
=
0
.4
5
6
y
es
1
p
3
6
.3
rs
1
8
0
1
1
3
1
E
x
o
n
1
9
0
2
4
C
T
P
as
se
d
3
3
6
(8
9
.4
)
C
C
(2
7
.0
)
C
T
(5
2
.0
)
T
T
(2
1
.0
)
T
=
0
.4
7
3
y
es
rs
2
2
7
4
9
7
6
E
x
o
n
5
4
5
1
5
C
T
c
P
as
se
d
3
6
0
(9
5
.7
)
C
C
(8
9
.8
)
C
T
(1
0
.2
)
T
T
(0
.0
)
T
=
0
.0
5
2
y
es
rs
4
8
4
6
0
4
9
3
0 u
tr
6
0
1
3
2
C
A
P
as
se
d
3
2
4
(8
6
.2
)
C
C
(5
5
.0
)
C
A
(3
4
.0
)
A
A
(1
1
.0
)
A
=
0
.2
8
6
y
es
rs
1
5
3
7
5
1
4
3
0 u
tr
8
3
1
0
3
C
G
P
as
se
d
2
1
2
(5
6
.4
)
C
C
(9
5
.0
)
C
G
(5
.0
)
G
G
(0
.0
)
G
=
0
.0
0
2
y
es
M
T
R
A
C
0
1
3
2
6
8
.5
E
N
S
G
0
0
0
0
0
1
1
6
9
8
4
rs
4
6
5
9
7
2
5
In
tr
o
n
1
3
C
G
P
as
se
d
3
5
2
(9
3
.6
)
C
C
(3
0
.0
)
C
G
(4
8
.0
)
G
G
(2
2
.0
)
G
=
0
.4
5
6
y
es
1
q
4
3
rs
1
8
0
5
0
8
E
x
o
n
5
5
0
3
9
6
G
A
P
as
se
d
3
4
4
(9
1
.5
)
A
A
(7
2
.0
)
A
G
(2
5
.0
)
G
G
(3
.0
)
G
=
0
.1
5
2
n
o
rs
2
2
7
5
5
6
6
In
tr
o
n
5
5
1
0
1
5
C
T
P
as
se
d
2
8
9
(7
6
.9
)
T
T
(3
0
.1
)
T
C
(2
1
)
C
C
(4
8
.9
)
C
=
0
.4
5
5
y
es
rs
2
8
5
3
5
2
2
3
0 u
tr
6
7
5
9
5
2
C
A
F
A
IL
E
D
y
es
rs
2
8
5
3
5
2
3
3
0 u
tr
6
8
7
3
7
2
C
A
P
as
se
d
3
3
6
(8
9
.4
)
C
C
(3
7
.0
)
C
A
(4
2
.0
)
A
A
(2
1
.0
)
A
=
0
.4
1
9
y
es
rs
6
6
7
6
8
6
6
3
0 u
tr
7
1
1
6
5
2
C
A
c
P
as
se
d
3
4
0
(9
0
.4
)
C
C
(3
0
.0
)
C
A
(4
6
.0
)
A
A
(2
4
.0
)
A
=
0
.4
7
0
y
es
M
T
R
R
A
C
0
1
0
3
4
6
.6
E
N
S
G
0
0
0
0
0
1
2
4
2
7
5
rs
3
2
6
1
1
8
5
0 u
tr
1
2
C
A
c
P
as
se
d
3
4
0
(9
0
.4
)
A
A
(7
7
.0
)
A
C
(2
0
.0
)
C
C
(3
.0
)
C
=
0
.1
3
2
y
es
5
p
1
5
.3
-
p
1
5
.2
rs
1
8
0
1
3
9
4
E
x
o
n
2
4
3
8
6
G
A
P
as
se
d
3
5
2
(9
3
.6
)
A
A
(3
2
.0
)
A
G
(4
4
.0
)
G
G
(2
4
.0
)
G
=
0
.4
6
3
y
es
rs
1
5
3
2
2
6
8
E
x
o
n
9
6
4
4
4
C
T
P
as
se
d
3
4
8
(9
2
.5
)
C
C
(4
1
..
4
)
C
T
(4
6
..
2
)
T
T
(1
2
.4
)
T
=
0
.3
5
6
y
es
rs
2
3
0
3
0
8
0
E
x
o
n
9
8
8
9
1
A
T
P
as
se
d
3
2
4
(8
6
.2
)
T
T
(9
9
.0
)
T
A
(1
.0
)
A
A
(0
.0
)
A
=
0
.0
0
5
y
es
Biochem Genet
123
T
a
b
le
1
co
n
ti
n
u
ed
G
en
e
A
cc
es
si
o
n
N
o
.
E
n
se
m
b
le
g
en
e
S
N
P
ID
R
eg
io
n
P
o
si
ti
o
n
a
P
an
el
P
as
se
d
\
F
ai
le
d
b
N
u
m
b
er
o
f
ca
ll
ed
g
en
o
ty
p
e
G
en
o
ty
p
e
d
is
tr
ib
u
ti
o
n
n
(%
)
A
ll
el
e
fr
eq
u
en
cy
V
al
id
at
io
n
st
at
u
s
rs
1
0
0
6
4
6
3
1
E
x
o
n
1
7
4
2
0
3
C
G
c
P
as
se
d
3
6
0
(9
5
.7
)
G
G
(9
8
.0
)
G
C
(2
.0
)
C
C
(0
.0
)
C
=
0
.0
1
0
y
es
rs
1
6
8
7
9
3
3
4
E
x
o
n
2
3
0
2
0
3
C
G
P
as
se
d
3
3
2
(8
8
.3
)
C
C
(1
0
0
)
C
G
(0
.0
)
G
G
(0
.0
)
G
=
0
.0
0
n
o
rs
8
6
5
9
3
0 u
tr
3
2
3
4
7
1
A
T
P
as
se
d
3
4
8
(9
2
.5
)
A
A
(3
6
.0
)
A
T
(5
0
.0
)
T
T
(1
4
.0
)
T
=
0
.3
9
0
y
es
N
N
M
T
A
P
0
0
2
5
1
8
.3
E
N
S
G
0
0
0
0
0
1
6
6
7
4
1
rs
5
6
6
7
7
5
5
0 u
tr
1
4
C
T
P
as
se
d
3
2
4
(8
6
.2
)
C
C
(6
2
.5
)
C
T
(3
5
.5
)
T
T
(2
)
T
=
0
.2
0
0
y
es
1
1
q
2
3
.1
rs
5
1
1
4
3
0
5
0 u
tr
3
1
9
3
3
C
G
F
A
IL
E
D
n
o
rs
1
0
8
9
1
6
3
9
5
0 u
tr
8
3
7
4
2
C
A
c
P
as
se
d
3
3
6
(8
9
.4
)
C
C
(7
0
.0
)
C
A
(2
6
.0
)
A
A
(4
.0
)
A
=
0
.1
6
5
n
o
rs
4
6
4
6
3
3
5
ex
o
n
4
1
6
8
3
1
A
T
P
as
se
d
3
6
8
(9
7
.9
)
T
T
(7
0
.0
)
T
A
(2
7
.0
)
A
A
(3
.0
)
A
=
0
.1
6
8
y
es
rs
3
8
1
9
1
0
0
In
tr
o
n
4
2
2
1
7
4
C
T
P
as
se
d
3
6
0
(9
5
.7
)
T
T
(6
0
.0
)
T
C
(3
4
.0
)
C
C
(6
.0
)
C
=
0
.2
3
0
y
es
P
O
N
1
A
C
0
0
4
0
2
2
.1
E
N
S
G
0
0
0
0
0
0
0
5
4
2
1
rs
8
5
4
5
6
0
ex
o
n
1
1
A
T
P
as
se
d
3
5
2
(9
3
.6
)
T
T
(4
1
.0
)
T
A
(4
9
.0
)
A
A
(1
0
.0
)
A
=
0
.3
4
5
y
es
7
q
2
1
.3
rs
6
6
2
ex
o
n
8
6
3
8
6
G
A
P
as
se
d
3
4
4
(9
1
.5
)
A
A
(5
1
.0
)
A
G
(3
9
.0
)
G
G
(1
0
.0
)
G
=
0
.2
9
4
y
es
rs
3
9
1
7
5
9
4
ex
o
n
9
6
4
5
6
G
A
P
as
se
d
3
5
6
(9
4
.7
)
G
G
(1
0
0
)
G
A
(0
.0
)
A
A
(0
.0
)
A
=
0
.0
0
0
y
es
P
O
N
2
A
C
0
0
5
0
2
1
.1
E
N
S
G
0
0
0
0
0
1
0
5
8
5
4
rs
1
1
5
4
5
9
4
1
ex
o
n
1
3
C
G
P
as
se
d
3
5
6
(9
4
.7
)
C
C
(6
3
.8
)
C
G
(3
4
.6
)
G
G
(1
.6
)
G
=
0
.1
9
0
y
es
7
q
2
1
.3
rs
6
9
5
4
3
4
5
ex
o
n
6
2
4
0
3
C
G
F
A
IL
E
D
y
es
S
L
C
1
9
A
1
A
L
1
3
3
4
9
3
.3
E
N
S
G
0
0
0
0
0
0
3
5
9
2
8
rs
3
7
8
8
2
0
5
5
0 u
tr
1
6
G
A
P
as
se
d
3
0
4
(8
0
.8
)
G
G
(5
7
.0
)
G
A
(3
9
.0
)
A
A
(4
.0
)
A
=
0
.2
3
1
y
es
2
1
q
2
2
.3
rs
3
1
7
7
9
9
9
5
0 u
tr
6
4
6
2
5
C
T
P
as
se
d
3
0
4
(8
0
.8
)
T
T
(3
6
.3
)
T
C
(4
8
.9
)
C
C
(1
4
.8
)
C
=
0
.3
9
3
y
es
rs
1
0
5
1
2
6
6
5
0 u
tr
6
5
8
4
5
C
T
c
P
as
se
d
2
5
6
(6
8
.1
)
C
C
(3
4
.3
)
C
T
(5
1
.2
)
T
T
(1
4
.5
)
T
=
0
.4
0
1
y
es
rs
1
2
6
5
9
ex
o
n
1
2
8
2
2
5
C
T
F
A
IL
E
D
y
es
rs
1
0
5
1
2
9
6
3
0 u
tr
2
9
5
5
1
2
C
A
c
F
A
IL
E
D
y
es
S
H
M
T
1
A
C
1
2
7
5
3
7
.7
E
N
S
G
0
0
0
0
0
1
7
6
9
7
4
rs
6
3
8
4
1
6
in
tr
o
n
1
3
C
G
c
P
as
se
d
3
4
0
(9
0
.4
)
C
C
(3
2
.0
)
C
G
(5
0
.0
)
G
G
(1
8
.0
)
G
=
0
.4
3
3
y
es
1
7
p
1
1
.2
rs
1
9
7
9
2
7
7
ex
o
n
3
4
8
9
3
6
G
A
c
P
as
se
d
3
2
8
(8
7
.2
)
G
G
(9
9
.0
)
G
A
(1
.0
)
A
A
(0
.0
)
A
=
0
.0
0
3
y
es
rs
3
7
8
3
ex
o
n
3
4
9
7
2
3
C
G
F
A
IL
E
D
y
es
T
C
N
2
A
C
0
0
5
0
0
6
.2
E
N
S
G
0
0
0
0
0
1
8
5
3
3
9
rs
5
7
4
9
1
3
1
5
0 u
tr
1
6
G
A
P
as
se
d
3
2
4
(8
6
.2
)
G
G
(4
3
.0
)
G
A
(4
4
.0
)
A
A
(1
3
.0
)
A
=
0
.3
5
0
y
es
2
2
q
1
2
.2
rs
9
6
0
6
7
5
6
ex
o
n
5
0
3
8
4
C
T
c
F
A
IL
E
D
y
es
Biochem Genet
123
T
a
b
le
1
co
n
ti
n
u
ed
G
en
e
A
cc
es
si
o
n
N
o
.
E
n
se
m
b
le
g
en
e
S
N
P
ID
R
eg
io
n
P
o
si
ti
o
n
a
P
an
el
P
as
se
d
\
F
ai
le
d
b
N
u
m
b
er
o
f
ca
ll
ed
g
en
o
ty
p
e
G
en
o
ty
p
e
d
is
tr
ib
u
ti
o
n
n
(%
)
A
ll
el
e
fr
eq
u
en
cy
V
al
id
at
io
n
st
at
u
s
rs
1
8
0
1
1
9
8
ex
o
n
9
7
8
8
3
C
G
P
as
se
d
3
4
8
(9
2
.5
)
C
C
(4
2
.0
)
C
G
(4
5
.0
)
G
G
(1
3
.0
)
G
=
0
.3
5
4
y
es
rs
2
0
7
2
1
9
5
3
0 u
tr
2
0
9
1
1
1
A
T
P
as
se
d
1
5
6
(4
1
.5
)
T
T
(9
5
.0
)
T
A
(5
.0
)
A
A
(0
.0
)
A
=
0
.0
3
0
y
es
rs
1
0
4
1
8
3
0 u
tr
2
1
1
3
0
6
G
A
c
P
as
se
d
3
4
4
(9
1
.5
)
G
G
(5
8
.0
)
G
A
(3
8
.0
)
A
A
(4
.0
)
A
=
0
.2
3
3
y
es
T
Y
M
S
A
P
0
0
1
1
7
8
.4
E
N
S
G
0
0
0
0
0
1
7
6
8
9
0
rs
5
0
2
3
9
6
in
tr
o
n
1
5
C
T
P
as
se
d
3
0
2
(8
0
.3
)
C
C
(2
8
.1
)
C
T
(4
9
.0
)
T
T
(2
2
.9
)
T
=
0
.4
7
3
y
es
1
8
p
1
1
.3
2
rs
1
6
4
3
0
3
0 u
tr
1
4
2
0
8
2
C
A
c
P
as
se
d
1
4
0
(3
7
.2
)
C
C
(2
6
.0
)
C
A
(5
4
.0
)
A
A
(2
0
.0
)
A
=
0
.4
6
5
y
es
a
P
o
ly
m
o
rp
h
is
m
s
ar
e
n
u
m
b
er
ed
d
o
w
n
st
re
am
fr
o
m
th
e
fi
rs
t
S
N
P
at
it
s
5
0 o
f
th
e
g
en
o
m
ic
se
q
u
en
ce
b
S
p
o
ts
w
it
h
lo
w
fl
u
o
re
sc
en
ce
in
te
n
si
ty
o
r
am
b
ig
u
o
u
s
g
en
o
ty
p
e
ca
ll
s
ar
e
cl
as
si
fi
ed
as
fa
il
ed
c
P
ri
m
er
d
es
ig
n
ed
o
n
co
m
p
le
m
en
ta
ry
se
q
u
en
ce
d
N
u
cl
eo
ti
d
e
is
n
u
m
b
er
ed
fr
o
m
th
e
fi
rs
t
S
N
P
lo
ca
li
ze
d
in
th
e
T
Y
M
S
g
en
e
se
q
u
en
ce
Biochem Genet
123
Table 2 shows the results of the haplotype reconstruction analysis that we used in
association analyses. All haplotypes with an estimated frequency higher than 0.01
are reported.
Comparative Cost Analysis
Table 3 compares the costs of the GenomeLab SNPStream technology with respect
to a low-to-medium throughput technology, the electronic microchip technology,
and a classical manual approach such as RFLP analysis. The cost per SNP of the
electronic microchip technology was 3.85 times that of the SNPStream, and RFLP
analysis cost 4.26 to 9.92 times as much.
Discussion
The emerging role of single-nucleotide polymorphism in clinical association and
pharmacogenetic studies has created a need for high-throughput genotyping
technologies.
In this study, we describe the development, optimization, and validation of a
microarray approach using a commercial system, GenomeLab SNPStream tech-
nology, based on the minisequencing single-nucleotide primer extension principle,
for large-scale SNP detection in genes encoding molecules involved in Hcy
metabolism.
Mild hyperHcy is an established independent marker factor for atherothrombotic
diseases (Eikelboom et al. 1999; McCully 1996). The multifactorial pathogenesis of
this disorder includes environmental and genetic factors interacting to produce high
plasma Hcy levels (Fowler 2005; Gellekink et al. 2005).
Polymorphic variants in genes encoding enzymes involved in Hcy metabolism
(MTHFR, MTR, MTRR, CBS) (Frosst et al. 1995; Weisberg et al. 1998) influence
their expression and functional activities and have been proposed as susceptibility
factors for hyperHcy. Several studies are available in the literature that investigate
the genetic factors involved in hyperHcy, but they did not involve sufficient
numbers of patients and/or SNPs to assure statistically valid conclusions (Lewis
et al. 2005).
The heterogeneous nature of this complex trait highlights the need to study a
larger number of samples and SNPs to perform genetic association studies useful in
the evaluation of the underlying genetic causes of hyperHcy and of the mechanisms
at the basis of the beginning and of the progression of cardiovascular diseases.
Moreover, understanding the genetic architecture of the complex polygenic trait,
namely hyperHcy, or in general the misregulation of methionine metabolism is a
fundamental goal of the biological and medical research involved in other fields
such as cancer and neurological disorders (Gellekink et al. 2005; Sharma et al 2006;
Kwok 2001).
Association studies need to genotype a dense set of SNPs in a large panel of
individuals and to test each SNP, or set of local haplotypes constructed from the
SNP data, in the genotype-phenotype association. Even with some a priori
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Table 2 Haplotype frequency
Haplotypea,b Frequency Haplotypea,b Frequency Haplotypea,b Frequency
MTHFR GCP2 CBS
taccc 0.430 aa 0.514 cgtg 0.428
cccac 0.222 at 0.314 cgcg 0.412
caccc 0.219 ga 0.165 cgcc 0.078
cctac 0.029 Others 0.007 cgtc 0.037
cccag 0.024 tgcg 0.024
cacac 0.019 MTR tgcc 0.012
tcccc 0.017 gacaa 0.419 Others 0.009
ccccc 0.012 catcc 0.381
tatcc 0.011 cgtcc 0.131 MTHFD1
others 0.017 catca 0.024 ataacca 0.236
ggcaa 0.015 acacccg 0.186
NNMT gaccc 0.011 ataaccg 0.171
cctt 0.518 Others 0.019 acaaccg 0.100
tctt 0.153 acaacca 0.062
ccac 0.091 RFC1 acaccca 0.062
catt 0.064 gtc 0.402 ataatcg 0.046
caac 0.039 gct 0.359 atacccg 0.035
cctc 0.032 atc 0.198 ataccca 0.024
catc 0.031 act 0.037 acaatcg 0.021
tcac 0.019 Others 0.004 ataatca 0.019
tctc 0.010 acactcg 0.011
tatc 0.010 TCN2 Others 0.027
taac 0.010 gctg 0.356
Others 0.023 agtg 0.288 MTRR
gcta 0.210 aactgct 0.242
BHMT2 ggtg 0.056 agctgca 0.241
at 0.568 actg 0.038 agttgca 0.178
ac 0.249 acta 0.021 aattgca 0.158
gc 0.165 gcag 0.014 cactgct 0.090
gt 0.017 Others 0.017 aactgca 0.015
aattgct 0.010
BHMT TYMS Others
tca 0.383
ttca 0.287 cac 0.346 SHMT
ccta 0.254 cca 0.138 cg 0.563
ccct 0.161 tac 0.074 gg 0.433
ccca 0.084 ccc 0.042 Others 0.004
tcta 0.079 tcc 0.010
tcct 0.051 Others 0.007 AHCY
ctca 0.036 ac 0.823
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knowledge of a candidate gene region contributing to a disease phenotype, a large
number of SNPs need to be genotyped in an association study to ensure one of the
genotyped SNPs is causative or is in strong linkage disequilibrium with the
causative site. It is also important that SNPs are genotyped in a very large panel of
individuals to provide sufficient power to detect variants that may have only subtle
phenotypic effects.
During the last decade the wide-ranging application of SNP in research and
molecular diagnostics has required further development of robust, flexible, cost-
effective technology platforms for scoring genotypes in large numbers of samples to
evaluate the genotype–phenotype correlation. Moreover, after the pathogenetic role
of a polymorphism/mutation is identified, clinical diagnosis (diagnostic test) for
analysis of many SNPs in large sample sets will be required, which must satisfy the
quality features needed in the routine of a molecular genetic laboratory. A plethora
of SNP genotyping platforms is currently available (Kwok 2001; Syvanen 2001,
2005), offering different advantages and disadvantages with respect to the
characteristics of the technology (principle, cost, automation) and to the type of
study to be performed.
Table 2 continued
Haplotypea,b Frequency Haplotypea,b Frequency Haplotypea,b Frequency
tcca 0.019 cc 0.175
others 0.029 Others 0.002
a All SNPs in haplotypes are reported from 50 to 30 end of the relative gene, excluding failed SNPs
b All haplotypes with an estimated frequency lower than 0.01 are reported as ‘‘others’’
Table 3 Cost of SNP detection by three methods
Method Suppliesa
€
Technician Total running cost per
SNP €
Total time
consumedb hours
Hands-on time
hours
Wages
€
RFLP 2–5 216 96 0.26 2.26–5.26
Microelectronic
Chipc
2 31 14 0.04 2.04
GenomeLab
SNPStream
0.50 26 12 0.03 0.53
a ‘‘Supplies’’ includes all materials common to the three genotyping methods (Thermowell plates, DNA
polymerase, deoxynucleotides, primers, Thermowell seals, tips) and materials specific to a method: for
RFLP, agarose gel, Tris-acetate-EDTA buffer, DNA molecular weight markers, Polaroid film to photo-
graph DNA fragments and restriction endonucleases; for microelectronic chip, Macherey-Nagel 96-well
plates, Nanogen cartridges, universal reporters, histidine buffer, high and low salt buffers; for
GenomeLab SNPStream, SNPware Core Reagent kit, SNPware two dideoxynucleotide extension mix kit,
SBE clean-up reagent, extension oligonucleotides
b Time consumed when genotyping 384 samples for 12 SNPs
c According to our optimized protocol previously published (Giusti et al. 2004)
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Among the available advanced technologies, first we chose low-throughput
Nanogen technology (100–1400 SNPs for chip) (Giusti et al. 2004) and more
recently high-throughput GenomeLab SNPStream technology, based on the primer
extension principle (Denomme and Van Oene 2005). The latter system uses
fluorescent multiplex SNP-IT primer extension assays for allele determination of
previously discovered SNPs and allows genotyping of up to 890,000 SNP genotypes
per day, with only 4 ng of genomic DNA (Huang et al. 2004).
In the current study we selected and analyzed SNPs in 17 genes that may play a
role in modulating Hcy plasma levels and/or DNA methylation reactions, so
altering genetic stability and gene expression. In each gene we identified several
polymorphisms independent from their known role in influencing Hcy levels and
DNA methylation reactions. We chose SNPs according to their demonstrated or
putative function evaluated on the basis of literature data, their localization in the
promoter or other regulatory regions or exons, and their potential utility in
haplotype reconstruction.
Among the 72 selected SNPs, 57 passed all the steps in the software- and
technician-surveilled quality check and were thus suitable for the genotyping
analysis. The conversion rate of 79.2% rose to 81.7% if we excluded the panel with
the higher number of failed SNPs among the six designed panels.
Adherence to Hardy-Weinberg equilibrium (HWE) is a common criterion to
assess the quality of a genotyping assay, as a deviation can suggest incorrect
genotype assignments (Hosking et al. 2004). However, selection, mutation, or
migration can also cause deviation from HWE, and the power to detect these
processes increases with the sample size. Of our 57 converted assays, no SNP
showed a deviation from HWE.
In the first analysis, our data showed a call rate higher than 90%, meaning that
less than 10% of the samples needed to be reanalyzed. This is an important issue, as
the higher the call rate, the lower the need for further analysis, which reduces costs
and time of analysis and increases the benefit of automation.
The analysis of linkage disequilibrium of the SNPs and of the haplotype
reconstruction indicates that the selected SNPs could be suitable to investigate and
could illuminate the role of genes involved in Hcy metabolism in determining
plasma Hcy levels and clinical phenotypes.
In this study we compared data from two technologies available in our
laboratory, the Nanogen technology and the GenomeLab SNPStream technology.
Our data demonstrated 99.2% concordance between the results obtained by the two
technologies. We observed that six of the seven discordant samples were failed by
the Nanogen technology because of their low signal-to-noise ratio. The repetition of
PCR and analysis by Nanogen technology of the six samples confirmed the results
obtained by the GenomeLab SNPStream technology. Concerning one sample, the
repetition of the analysis by the two technologies confirmed the discordant result.
The direct sequencing analysis showed that the correct genotype was that obtained
using the GenomeLab SNPStream technology. This datum confirms the expected
higher accuracy of primer extension based technologies in allele discrimination.
Genomelab SNPStream is a cost-effective and time-saving alternative. In fact,
the cost of this high-throughput technology is a quarter that of the Nanogen
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technology and can be as little as a tenth the cost of a classical RFLP genotyping
assay. Moreover, this technology permits shorter analysis time compared with
Nanogen and RFLP approaches (16% and 88%, respectively), resulting in the
possibility of increasing the number of genotyped SNPs over which to amortize the
cost of the instrument.
In conclusion, our data highlight that the described approach using the
commercially available high-throughput GenomeLab SNPStream technology offers
considerable advantages for SNP genotyping on a large scale, representing a useful
tool to investigate the genotype-phenotype correlation and the association between
the methionine cycle genes and hyperHcy and/or diseases correlated to methionine
metabolism alterations, as well as other complex multifactorial traits.
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